Health Care Distributors

CHINA REFORM HEALTH

CHINA REFORM HEALTH released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 50.52 M, actual EPS CNY -0.0497

CHINA REFORM HEALTH FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

CHINA REFORM HEALTH to Release FY2025 Earnings on April 29 After-Market (BJT), Forecast Revenue CNY 374.9 M, EPS CNY -0.03

CHINA REFORM HEALTH released FY2025 9 Months earnings on October 29 Pre-Market BJT, actual revenue CNY 170.4 M, actual EPS CNY -0.1414

CHINA REFORM HEALTH released FY2025 Q3 earnings on October 29 Pre-Market (BJT), actual revenue CNY 74.87 M, actual EPS CNY -0.0401

CHINA REFORM HEALTH to Release FY2025 Q3 Earnings on October 30, Pre-Market BJT

CHINA REFORM HEALTH released FY2025 Q2 earnings on August 27 After-Market (BJT), actual revenue CNY 45.06 M, actual EPS CNY -0.0547

CHINA REFORM HEALTH released FY2025 Semi-Annual Earnings on August 27 After-Market (BJT), with actual revenue of CNY 95.53 M and EPS of CNY -0.1012

CHINA REFORM HEALTH to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Guo Xin Health's ESG Rating Significantly Improved

Guoxinhaojian Elects New Chairman and CEO

CHINA REFORM HEALTH released FY2025 Q1 earnings on April 24 After-Market BJT, actual revenue CNY 50.47 M, actual EPS CNY -0.0465

CHINA REFORM HEALTH released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 156.72 M, actual EPS CNY 0.021

CHINA REFORM HEALTH released FY2024 earnings on April 24 After-Market BJT, actual revenue CNY 356.9 M (forecast CNY 598.11 M), actual EPS CNY -0.0106 (forecast CNY 0.08)

China Reform Health to Release FY2025 Q1 Earnings on April 25 After-Market BJT

CHINA REFORM HEALTH to Release FY2024 Earnings on April 25 After-Market BJT, Forecasted Revenue CNY 598.11 M, EPS CNY 0.08

Zhonghai Heng and Guoxin Development Plan to Increase Stake in Guoxin Health, Amount Not Less Than 100 Million Yuan

China Reform Health to Announce Q3 2024 Earnings on October 26, 2024

Guoxin Health releases Q3 2024 report

CHINA REFORM HEALTH released FY2024 9 Months Earnings on October 25 After-Market (BJT), actual revenue CNY 200.18 M, actual EPS CNY -0.0315

000503

688337

300965

605168

603138

On October 9th, a total of 11 listed companies had their restricted shares unlocked, with a total market value of approximately 24.303 billion yuan. The specific situation of the restricted share unlocks today is as follows: 

| Stock Abbreviation | Stock Code | Restricted Share Type | Number of Unlocks |
| -------------------- | ------------ | ----------------------- | -------------------- |
| CHINA REFORM HEALTH | 000503 | Equity Incentive Restricted Circulation | 1.6798 million |
| Kangyuan Pharmaceutical | 600557 | Equity Incentive Restricted Circulation | 315,500 |
| Sentech Co., Ltd. | 603098 | Equity Incentive Restricted Circulation | 270,000 |
| SRX | 605168 | Equity Incentive Restricted Circulation | 165,300 |
| VASTDATA | 603138 | Equity Incentive Restricted Circulation | 5.6629 million |
| Tianyi Medical | 301097 | Extended Restricted Lock-up Period Circulation | 40.6 million |
| Minglida | 301268 | Extended Restricted Lock-up Period Circulation | 190 million |
| HENGYU DATACOM | 300965 | Extended Restricted Lock-up Period Circulation | 35.1045 million |
| RIGOL | 688337 | 1.18 billion |
| Zhongfu Shenying | 688295 | 2.98 billion |
| Changguang Huaxin | 688048 | 700 million |

Zhitong

RIGOL

HENGYU DATACOM

VASTDATA

Zhitong A-share lock-up release overview | October 9

CHINA REFORM HEALTH announced that its controlling shareholder China Oceanwide Holdings and its concerted party China Reform Development completed their shareholding increase plan on September 26, 2025, with an increase amount of approximately 100 million yuan, raising their shareholding ratio from 26.48% to 27.44%. The purpose of the increase is based on confidence in the company's development and to stabilize the stock price. The increase is compliant and has not affected the listing conditions and actual control rights, with a commitment not to reduce holdings within the statutory period

CHINA REFORM HEALTH: The controlling shareholder and its concerted parties have completed the billion-yuan increase plan

CHINA REFORM HEALTH announced that CHINA REFORM DEVELOPMENT increased its holdings by a total of 7.6813 million shares through centralized bidding from September 17, 2025, to September 19, 2025, accounting for 0.78% of the company's total share capital, with a transaction amount of 81.1461 million yuan; after the increase, its holdings reached 31.8053 million shares, accounting for 3.24%. China Oceanwide and its concerted parties collectively hold 268 million shares, accounting for 27.26%. This equity change touches on an integer multiple of 1%, and the increase plan is still being implemented

CHINA REFORM HEALTH: Unanimous shareholders increased their holdings by 7.6813 million shares

On the evening of September 4th, CHINA REFORM HEALTH announced that the company's board of directors recently learned that independent director Bai Yan unfortunately passed away due to illness on August 31, 2025. The company and its board of directors express their deep condolences for Bai Yan's passing and extend heartfelt sympathies to his family

CHINA REFORM HEALTH: The company's independent director Bai Yan has passed away due to illness

According to the Zhitong Finance APP, CHINA REFORM HEALTH released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 95.5301 million yuan, a year-on-year decrease of 30.47%. The net loss attributable to shareholders of the listed company was 99.0907 million yuan, and the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 98.8113 million yuan, with a basic loss per share of 0.1012 yuan

CHINA REFORM HEALTH released its performance for the first half of the year, with a net loss attributable to the parent company of 99.0907 million yuan

688246

601600

02600

On June 13th, a total of 7 listed companies had their restricted shares unlocked, with a total market value of approximately 1.534 billion yuan. The specific situation of the restricted shares unlocking today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares GuoXin Health 000503 Additional Issuance A Shares Legal Person Allocation Listed 24.124 million CHALCO 601600 Equity Incentive Restricted Circulation 32.8082 million Sanxiang New Materials 603663 Equity Incentive Restricted Circulation 560,000 Ligong Optical Science 300557 Equity Incentive Restricted Circulation 103,300 Rongtai Co., Ltd. 605133 Equity Incentive Restricted Circulation 416,600 Hongbai New Materials 605366 Equity Incentive Restricted Circulation 2.6426 million GOODWILL 688246 3,663,600

GOODWILL

CHALCO

RTGF

Jiangxi Hungpai New Material

WUTOS

SXXC

Overview of the lifting of restrictions on the sale of A-shares | June 13

On May 6th, CHINA REFORM HEALTH announced the election of Li Yonghua as the chairman of the 12th board of directors and the appointment of Yuan Hongquan as the company's general manager

CHINA REFORM HEALTH: Elected Li Yonghua as Chairman

According to the Zhitong Finance APP, CHINA REFORM HEALTH announced that its controlling shareholder China Oceanwide Holdings Group Co., Ltd. (referred to as "China Oceanwide") and its concerted party Guoxin Development Investment Management Co., Ltd. (referred to as "Guoxin Development") plan to increase their holdings in the company within the next 6 months through methods permitted by the Shenzhen Stock Exchange, with an intended increase of no less than RMB 100 million and no more than RMB 200 million

The controlling shareholder of CHINA REFORM HEALTH and its concerted parties plan to invest 100 million to 200 million yuan to increase their shareholding

603658

603111

300298

300239

Yesterday, 18 companies announced stock repurchase plans, among which 3 companies disclosed their repurchase plans for the first time, 4 companies reported implementation progress, and 11 companies have completed their repurchases. In the repurchase plans, Sinocare, Ruoyu Chen, and CHINA REFORM HEALTH had the highest amounts, at 300 million yuan, 200 million yuan, and 636,500 yuan, respectively. In terms of implementation progress, Kalet, Dongbao Bio-Tech, and Yachuang Electronics had the highest repurchase amounts, at 43.1021 million yuan, 40.1431 million yuan, and 4.6771 million yuan, respectively. Among those that have completed repurchases, Autobio, Shui Jing Fang, and KN had the highest amounts, at 445 million yuan, 125 million yuan, and 100 million yuan, respectively

Autobio

Sinocare

Dongbao Bio-Tech

SCSF

Colorlight

Overview of A-share Stock Buybacks: 18 Companies Disclosed Buyback Progress Yesterday

300078

002065

300244

DRG/DIP concept stocks surged in the afternoon, with Donghua Software and CHINA REFORM HEALTH hitting the daily limit, Weining Health and Century rising over 10%, and GOODWILL and Dian Diagnostics following suit

Century

DHCC

Dian Diagnostics

Winning Health

DRG/DIP concept stocks surged in the afternoon, with DHCC and CHINA REFORM HEALTH hitting the limit up

CHINA REFORM HEALTH(000503.SZ)